Nicola Silvestris

Overview

Best Publications

• Liquid biopsy and tumor heterogeneity in metastatic solid tumors: the potentiality of blood samples

  Marco Russano;Andrea Napolitano;Giulia Ribelli;Michele Iuliani

  204
  Citations

• Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells.

  Amalia Azzariti;Rosa Maria Iacobazzi;Roberta Di Fonte;Letizia Porcelli

  156
  Citations

• Natural history of bone metastasis in colorectal cancer: final results of a large Italian bone metastases study

  D. Santini;M. Tampellini;B. Vincenzi;T. Ibrahim

  149
  Citations

• Incidence of patients with bone metastases at diagnosis of solid tumors in adults: a large population-based study.

  Jin-Feng Huang;Jianfei Shen;Xiao Li;Ramesh Rengan

  148
  Citations

• Hospital admission of cancer patients: avoidable practice or necessary care?

  Gianmauro Numico;Antonella Cristofano;Alessandro Mozzicafreddo;Olga Elisabetta Cursio

  146
  Citations

• Prognostic vs predictive molecular biomarkers in colorectal cancer: is KRAS and BRAF wild type status required for anti-EGFR therapy?

  Sergio Rizzo;Giuseppe Bronte;Daniele Fanale;Lidia Corsini

  137
  Citations

• Current approaches for combination therapy of cancer: The role of immunogenic cell death

  Zahra Asadzadeh;Elham Safarzadeh;Sahar Safaei;Ali Baradaran

  116
  Citations

• Dasatinib: an anti-tumour agent via Src inhibition.

  Antonio Gnoni;Ilaria Marech;Nicola Silvestris;Angelo Vacca

  116
  Citations

• The role of inflammatory cytokines and tumor associated macrophages (TAMs) in microenvironment of pancreatic cancer.

  Saeed Farajzadeh Valilou;Mahsa Keshavarz-Fathi;Mahsa Keshavarz-Fathi;Nicola Silvestris;Antonella Argentiero

  111
  Citations

• Expression and prognostic value of VEGFR-2, PDGFR-β, and c-Met in advanced hepatocellular carcinoma

  Jie Sheng Chu;Fei Jiao Ge;Bo Zhang;Yan Wang

  111
  Citations

• Adjuvant colon cancer chemotherapy: where we are and where we'll go.

  L. Lombardi;F. Morelli;S. Cinieri;D. Santini

  109
  Citations

• Human epidermal growth factor receptor 2 (HER2) in gastric cancer: a new therapeutic target.

  F. De Vita;F. Giuliani;N. Silvestris;G. Catalano

  105
  Citations

• Immunotherapy for colorectal cancer: where are we heading?

  Debora Basile;Silvio Ken Garattini;Marta Bonotto;Elena Ongaro

  104
  Citations

• High density of tryptase-positive mast cells in human colorectal cancer: a poor prognostic factor related to protease-activated receptor 2 expression.

  Andrea Malfettone;Nicola Silvestris;Concetta Saponaro;Girolamo Ranieri

  100
  Citations

• Immune inflammation indicators and implication for immune modulation strategies in advanced hepatocellular carcinoma patients receiving sorafenib

  Andrea Casadei Gardini;Emanuela Scarpi;Luca Faloppi;Mario Scartozzi

  99
  Citations

• Angiogenesis in pancreatic ductal adenocarcinoma: A controversial issue

  Vito Longo;Oronzo Brunetti;Antonio Gnoni;Stefano Cascinu

  96
  Citations

• Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study.

  Antonella Argentiero;Simona De Summa;Roberta Di Fonte;Rosa Maria Iacobazzi

  96
  Citations

• New findings on primary and acquired resistance to anti-EGFR therapy in metastatic colorectal cancer: do all roads lead to RAS?

  Giuseppe Bronte;Nicola Silvestris;Marta Castiglia;Antonio Galvano

  95
  Citations

• Molecularly targeted endocrine therapies for breast cancer.

  L. Orlando;P. Schiavone;P. Fedele;N. Calvani

  92
  Citations

• Metformin and insulin impact on clinical outcome in patients with advanced hepatocellular carcinoma receiving sorafenib: Validation study and biological rationale.

  Andrea Casadei Gardini;Luca Faloppi;Serena De Matteis;Francesco Giuseppe Foschi

  90
  Citations